Combined Management of Malignant Teratoma of the Testis

Peckham, M. J.; Barrett, A; McElwain, T. J.; Hendry, W. F.

doi:10.1016/s0140-6736(79)90288-5

Cited by 249 publications

(81 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ninety per cent of the patients with testicular cancer are now cured (Peckham, 1988;Fossa et al, 1988). As the mean age of patients with this malignancy is about 35 years, most of them will live for 30-40 years after treatment.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy

Fosså

Langmark²,

Aass³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…In these large studies the relation to treatment is, however, not always considered specifically. The objective of the present paper is to study the (Peckham et al, 1979).…”

mentioning

confidence: 99%

Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy

Fosså

Langmark²,

Aass³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

“…It is obvious that all patients are not seen at our center. This could be either because they are not diag- (Peckham et al, 1979). Tumours in undescended testis formed a proportion that is much higher than the current western figures and reflects the underdeveloped health services in peripheral areas (Einhorn et al, 1979).…”

Section: Methodsmentioning

confidence: 98%

“…Besides clinical examination, all patients had complete hemogram, routine biochemistry, markers like b-human chorionic gonadotrophin and alpha fetoprotein, radiograph of the chest, and CT scans. Patients were staged using the Royal Marsden Hospital classification (Peckham et al, 1979). Histological staging was done using the WHO classification (Mostofi & Sobin, 1977 Survival in months Figure 1 Probability of survival seminoma (stages II-IV) 16 pts.…”

Section: Methodsmentioning

confidence: 99%

Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990

Raina

Shukla²,

Rath³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Marsden stage IIC, III or IV disease were eligible (Peckham et al, 1979). Patients were randomized by telephone call to the MRC Cancer Trials Office, and allocated either 4 cycles of etoposide and cisplatin (EP) or 4 cycles of single agent carboplatin (C).…”

mentioning

confidence: 99%

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma

et al. 2000

View full text Add to dashboard Cite

The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent carboplatin (C) at a dose of 400 mg/m 2 to be corrected for glomerular filtration rate outside the range 81–120 ml min –1 and to be administered on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to exclude a reduction in the 3-year progression-free survival in patients allocated to carboplatin of between 10 and 15%, requiring initially a target accrual of 250 patients (90% power significance level 5% (one-sided)). The trial closed after 130 patients had been randomized following recommendation by an independent data monitoring committee. At a median follow-up time of 4.5 years, 81% of patients had been followed up for at least 3 years and 19 patients have died. The estimated PFS rate (95% Confidence Intervals (CI)) at 3 years was 71% (60–82%) in patients allocated C and 81% (71–90%) in those allocated EP; the 95% CI for the difference in 3 year PFS was – 6% to +19%. The hazard ratio of 0.64 (95% CI 0.32–1.28) favoured EP but the difference was not statistically significant (log rank chi-squared = 1.59 P = 0.21). The 3-year survival rate was 84% (75–92%) in those allocated C, and 89% (81–96%) in those allocated EP. The hazard ratio for survival was 0.85 with 95% CI, 0.35–2.10, log rank chi-squared = 0.12, P = 0.73. The trial has not demonstrated statistically significant differences in the major survival endpoints comparing single agent carboplatin with a combination of etoposide + cisplatin. This cannot be taken as an indication of equivalence since the limited size of this trial rendered it unable to exclude a 19% lower progression-free survival and survival in those treated with single agent carboplatin which would be important clinically. Standard initial chemotherapy for advanced seminoma should be based on cisplatin combinations and the role of carboplatin awaits the outcome of further studies. © 2000 Cancer Research Campaign http://www.bjcancer.com

show abstract

Combined Management of Malignant Teratoma of the Testis

Cited by 249 publications

References 7 publications

Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy

Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy

Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma

Contact Info

Product

Resources

About